521 related articles for article (PubMed ID: 30257515)
41. [
Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
[TBL] [Abstract][Full Text] [Related]
42. Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.
Victorino APOS; Meton F; Mardegan L; Festa J; Piranda DN; Araujo KB
J Geriatr Oncol; 2023 May; 14(4):101477. PubMed ID: 36990929
[TBL] [Abstract][Full Text] [Related]
43. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
[TBL] [Abstract][Full Text] [Related]
44. Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice.
Giuliani J; Insolda J; Pigozzi E; Bonetti A
Recenti Prog Med; 2020 Dec; 111(12):785-787. PubMed ID: 33362177
[No Abstract] [Full Text] [Related]
45. Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer.
Barone C; Bartolomeo MD; Lonardi S; Maiello E; Martinelli E; Moretto R; Strippoli A; Tamburini E; Zaniboni A; Pinto C
Future Oncol; 2021 May; 17(14):1749-1759. PubMed ID: 33464133
[TBL] [Abstract][Full Text] [Related]
46. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
[TBL] [Abstract][Full Text] [Related]
47. Trifluridine/tipiracil and regorafenib: new weapons in the war against metastatic colorectal cancer.
Weinberg BA; Marshall JL; Salem ME
Clin Adv Hematol Oncol; 2016 Aug; 14(8):630-8. PubMed ID: 27487107
[TBL] [Abstract][Full Text] [Related]
48. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer.
Grothey A; Bekaii-Saab TS; Yoshino T; Prager GW
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 2(1):1-24. PubMed ID: 33843903
[TBL] [Abstract][Full Text] [Related]
49. [Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].
Oki M; Nakamura A; Shinamura N; Sugaya T; Takagi K; Sugaya M
Gan To Kagaku Ryoho; 2018 Sep; 45(9):1297-1303. PubMed ID: 30237371
[TBL] [Abstract][Full Text] [Related]
50. Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.
Narita Y; Ogata T; Ishizuka Y; Sakakida T; Wakabayashi M; Kodama H; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ando M; Tajika M; Muro K
Sci Rep; 2024 Jun; 14(1):12658. PubMed ID: 38830895
[TBL] [Abstract][Full Text] [Related]
51. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
52. Improving survival in metastatic colorectal cancer through optimized patient selection.
Bekaii-Saab TS; Barzi A; Cusnir M
Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):1-20. PubMed ID: 38805297
[TBL] [Abstract][Full Text] [Related]
53. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
Cleary JM; Rosen LS; Yoshida K; Rasco D; Shapiro GI; Sun W
Invest New Drugs; 2017 Apr; 35(2):189-197. PubMed ID: 28111727
[TBL] [Abstract][Full Text] [Related]
54. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey.
Özet A; Dane F; Aykan NF; Yalçın Ş; Evrensel T; Özkan M; Karabulut B; Ormeci MN; Atasev O; Vidot L; Çiçin İ
Future Oncol; 2022 Sep; 18(29):3267-3276. PubMed ID: 36040321
[No Abstract] [Full Text] [Related]
55. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Tanaka N; Sakamoto K; Okabe H; Fujioka A; Yamamura K; Nakagawa F; Nagase H; Yokogawa T; Oguchi K; Ishida K; Osada A; Kazuno H; Yamada Y; Matsuo K
Oncol Rep; 2014 Dec; 32(6):2319-26. PubMed ID: 25230742
[TBL] [Abstract][Full Text] [Related]
56. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
[TBL] [Abstract][Full Text] [Related]
57. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Mansoor W; Arkenau HT; Alsina M; Shitara K; Thuss-Patience P; Cuffe S; Dvorkin M; Park D; Ando T; Van Den Eynde M; Beretta GD; Zaniboni A; Doi T; Tabernero J; Ilson DH; Makris L; Benhadji KA; Van Cutsem E
Gastric Cancer; 2021 Jul; 24(4):970-977. PubMed ID: 33713215
[TBL] [Abstract][Full Text] [Related]
58. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
Suenaga M; Wakatsuki T; Mashima T; Ogura M; Ichimura T; Shinozaki E; Nakayama I; Osumi H; Ota Y; Takahari D; Chin K; Seimiya H; Yamaguchi K
Invest New Drugs; 2020 Feb; 38(1):111-119. PubMed ID: 30838483
[TBL] [Abstract][Full Text] [Related]
59. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo.
Emura T; Suzuki N; Fujioka A; Ohshimo H; Fukushima M
Int J Oncol; 2005 Aug; 27(2):449-55. PubMed ID: 16010427
[TBL] [Abstract][Full Text] [Related]
60. Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Murgioni S; Rossini D; Marmorino F; Mennitto A; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Ann Oncol; 2017 May; 28(5):1015-1022. PubMed ID: 28453695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
